Full Text
EE397 Budget Impact Analysis of Nivolumab Plus Ipilimumab for the Management of Advanced Unresected Malignant Pleural Mesothelioma (MPM)

Abstract

Authors

I. Alfayoumi O. Aqel

Back to Volume 26, Supplemental Issue 6S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×